Form 8-K - Current report:
SEC Accession No. 0001437749-23-000803
Filing Date
2023-01-10
Accepted
2023-01-10 16:41:49
Documents
14
Period of Report
2023-01-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.03: Material Modifications to Rights of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K navb20230110_8k.htm   iXBRL 8-K 31120
2 EXHIBIT 4.1 ex_462810.htm EX-4.1 13382
  Complete submission text file 0001437749-23-000803.txt   195908

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA navb-20230110.xsd EX-101.SCH 4035
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20230110_def.xml EX-101.DEF 13506
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20230110_lab.xml EX-101.LAB 17660
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20230110_pre.xml EX-101.PRE 13473
8 EXTRACTED XBRL INSTANCE DOCUMENT navb20230110_8k_htm.xml XML 4280
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

EIN.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35076 | Film No.: 23521625
SIC: 2835 In Vitro & In Vivo Diagnostic Substances